Adele Gulfo is the Chief of Commercial Development, Roivant Sciences. Previously, she served as Chief Strategy Officer, EVP and Head of Global Commercial Development at Mylan. She is currently a director of Bemis, Inc. (BMS), serving on the company’s Audit Committee. As a member of Mylan’s Executive Leadership Team, she focused on their key growth drivers, including the company’s expansion into new geographies and the development and growth of its global Specialty pharmaceutical franchise. Previously, Gulfo served as president and general manager of Pfizer’s U.S. Primary Care business unit, which included the Managed Markets and Commercial Operations for all of Pfizer’s Biopharmaceutical business units. Under her leadership, Pfizer’s U.S. Primary Care business generated more than $13 billion in revenue. Earlier in her career at Pfizer, Gulfo was instrumental in the development, launch and commercial success of LIPITOR, which became the world’s best-selling medicine. She was also recognized for her leadership in marketing and medical education campaigns that helped to establish the significance of lowering cholesterol in preventing and managing heart disease.
Back to Innovation Growth Board